Malaria vaccine study pulled before it began
NCT ID NCT07208760
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to see if giving a single dose of an antibody called L9LS changes how well the R21/Matrix-M malaria vaccine works. It planned to enroll healthy adults and infants in Mali. However, the trial was withdrawn before any participants were enrolled, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- L9LS (a monoclonal antibody) and R21/Matrix-M malaria vaccine
- What this could lead to
- If successful, this could help design better malaria prevention strategies by understanding how antibodies and vaccines work together.
- What could go wrong
- The trial was withdrawn before enrolling anyone, so no results are available. It is unclear if the approach is safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sotuba Malaria Research and Training Center (MRTC)
Sotouba, Mali
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill make your blood deadly to malaria mosquitoes?
- Can a new vaccine stop malaria in its tracks?
- Can a new malaria vaccine slash childhood cases? a massive real-world test seeks answers.
- One shot, six months of malaria shield? a new trial tests a powerful antibody in children
- School health rooms and trained teachers: a new hope for Zambia's children?
- Experimental malaria vaccine aims to block parasite growth